Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Peter Clark, MA, MD, FRCP: A Payer Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Jun
10
Today In Oncology
New Research Links Low Alcohol Consumption to Elevated Health Risks
Digital Tool May Improve Patient Engagement in Oncology Clinical Trials
GLP-1 RAs May Reduce Risk of Obesity-Related Cancers
Teclistamab in Previously Treated Multiple Myeloma
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo